This Study Evaluates KRT-232, a Novel Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients With (p53WT) Merkel Cell Carcinoma Who Have Failed Anti-PD-1/ PD-L1 Immunotherapy
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the
treatment of patients with Merkel Cell Carcinoma (MCC) who have failed treatment with at
least one anti-PD-1 or anti-PD-L1 immunotherapy. Inhibition of MDM2 is a novel mechanism of
action in MCC.
This study is Phase 2, Open-Label, Single-Arm Study of KRT-232 in Patients with p53 Wild-Type
(p53WT) Merkel Cell Carcinoma